Boris Shore
Präsident bei NORTHERN POTASH CO.
Aktive Positionen von Boris Shore
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| NORTHERN POTASH CO. | Präsident | - | - |
| Vorstandsvorsitzender | - | - |
Karriereverlauf von Boris Shore
Ehemalige bekannte Positionen von Boris Shore
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| IMMUNE PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | - | - |
Ausbildung von Boris Shore
| Moscow University | Undergraduate Degree |
Statistik
International
| Russland | 3 |
| Vereinigte Staaten | 2 |
Operativ
| Chief Executive Officer | 1 |
| President | 1 |
| Undergraduate Degree | 1 |
Sektoral
| Process Industries | 2 |
| Consumer Services | 2 |
| Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| NORTHERN POTASH CO. | Process Industries |
| Private Unternehmen | 1 |
|---|---|
Immune Pharmaceuticals, Inc.
 Immune Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Immune Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Its lead product, Bertilimumab, is a human monoclonal antibody that binds eotaxin-1, a chemokine that attracts eosinophils to the site of inflammation. Bertilimumab has shown promising clinical activity in bullous pemphigoid and has been studied in other conditions including allergic rhinitis and ulcerative colitis, and may have application in other diseases, including atopic dermatitis, asthma, and other diseases. It is also developing NanoCyclo, a topical nano-encapsulated formulation of cyclosporine, for the treatment of atopic dermatitis (AD) and psoriasis. The company was founded by Daniel Gedeon Teper on March 9, 1993 and is headquartered in Englewood Cliffs, NJ. | Health Technology |
- Börse
- Insiders
- Boris Shore
- Erfahrung
